Skip to content

Advertisement

  • Meeting abstract
  • Open Access

C-erbB-2 overexpression in primary breast cancer: relationship to clinical and histopathological parameters of patients with breast cancer

  • 1,
  • 1, 3,
  • 2 and
  • 1
Breast Cancer Research20013 (Suppl 1) :A50

https://doi.org/10.1186/bcr378

  • Received: 10 May 2001
  • Published:

Keywords

  • Breast Cancer
  • Breast Tumor
  • Breast Carcinoma
  • Primary Breast Cancer
  • Invasive Ductal Carcinoma

Objective

Amplification of c-erbB-2 oncoprotein has been described in 10-35% of primary breast cancers. Breast tumors with immunohistochemical overexpression of c-erbB-2 protein seem to be more aggressive. We evaluated the impact of c-erbB-2 overexpression on clinical and histopathological parameters of patients with breast cancer.

Method

Primary tumors from 417 patients, who were treated at our Department for breast cancer, were studied. Immunostaining of c-erbB-2 oncoprotein was carried out utilizing the monoclonal antibody CB11.

Results

C-erbB-2 overexpression was seen in 72 out of 417 (17%) of primary breast tumors. Patients with positive immunohistochemistry (IHC) for c-erbB-2 were significantly younger (P = 0.015), on average. The number of involved lymph nodes was higher in patients with positive IHC (P = 0.014). Nearly all IHC positive tumors (98.6%) were invasive ductal carcinomas, whereas all but one lobular carcinoma were negative. Tumors with negative IHC more often demonstrated positive estrogen (P = 0.001) and proges-terone (P = 0.001) expression than did patients with positive IHC. There was a significant relation of c-erbB-2 IHC and nuclear grading, Ki67 and p53. No association was found with menopausal status, tumor size, T-staging and presence of metastases.

Conclusion

(1) Overexpression of c-erbB-2 oncoprotein in primary breast cancer tumors may be an indicator of the extent of lymph node metastases in patients. (2) Lobular carcinomas represent a defined subtype of breast carcinomas.

Authors’ Affiliations

(1)
Department of Obstetrics and Gynecology, Ulm, Germany
(2)
University of Freiburg, Germany
(3)
International Agency for Research on Cancer, Lyon, France

Copyright

Advertisement